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Abstract
Aims/hypothesis Hepatic steatosis is strongly associated
with hepatic and whole-body insulin resistance. It has
proved difficult to determine whether hepatic steatosis itself
is a direct cause of insulin resistance. In patients with
familial hypobetalipoproteinaemia (FHBL), hepatic steato-
sis is a direct consequence of impaired hepatic VLDL
excretion, independently of metabolic derangements. Thus,
patients with FHBL provide a unique opportunity to
investigate the relation between increased liver fat and
insulin sensitivity.
Methods We included seven male participants with FHBL
and seven healthy matched controls. Intrahepatic triacyl-
glycerol content and intramyocellular lipid content were
measured using localised proton magnetic resonance
spectroscopy (¹H-MRS). A two-step hyperinsulinaemic–
euglycaemic clamp, using stable isotopes, was assessed to
determine hepatic and peripheral insulin sensitivity.
Results ¹H-MRS showed moderate to severe hepatic steatosis
in patients with FHBL. Basal endogenous glucose production
(EGP) and glucose levels did not differ between the two
groups, whereas insulin levels tended to be higher in patients
comparedwithcontrols.Insulin-mediatedsuppressionofEGP
during lower dose insulin infusion and insulin-mediated
peripheral glucose uptake during higher dose insulin infusion
were comparable between FHBL participants and controls.
Baseline fatty acids and lipolysis (glycerol turnover) at
baseline and during the clamp did not differ between groups.
Conclusions/interpretation In spite of moderate to severe
hepatic steatosis, people with FHBL do not display a
reduction in hepatic or peripheral insulin sensitivity
compared with healthy matched controls. These results
indicate that hepatic steatosis per se is not a causal factor
leading to insulin resistance.
Trial registration: ISRCTN35161775
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common
feature of obesity and the metabolic syndrome [1, 2].
NAFLD is the result of hepatic fat accumulation due to an
increased flux of NEFA through the portal vein, reduced
hepatic fatty acid oxidation and increased hepatic de novo
lipogenesis, all of which are associated with central obesity
and insulin resistance [3]. Hyperinsulinaemic–euglycaemic
clamp studies have shown that increased intrahepatic
triacylglycerol (IHTG) content strongly correlates with
insulin resistance in liver, skeletal muscle and adipose
tissue across a large range of liver fat percentages.
Therefore, even small amounts of IHTG content were
associated with metabolic dysfunction [1, 4–8]. In addition,
results of animal studies have shown that hepatic fat
accumulation may interfere with insulin signalling in the
liver through activation of protein kinase Cε [9, 10],
suggesting a direct causal relationship between hepatic fat
accumulation and insulin resistance. However, in obese
humans it has been difficult to determine whether hepatic
fat accumulation per se causes insulin resistance since both
are features of metabolic derangements.
Familial hypobetalipoproteinaemia (FHBL) is a rare
disorder of lipoprotein metabolism (estimated prevalence
ranges from 1 in 500 to 1 in 1,000) and is characterised by
LDL-cholesterol and total apolipoprotein B (ApoB) levels
below the 5th percentile [11, 12]. Approximately 50% of
FHBL patients are carriers of a mutation in the APOB gene
[11] leading to the formation of a dysfunctional form of
ApoB. Since ApoB is the main component of VLDL,
mutations in APOB gene give rise to a defective VLDL
export system with a reduced capacity to export triacylgly-
cerol from the liver. As a consequence, mean triacylglycerol
content in the livers of FHBL participants, measured using
localised proton magnetic resonance spectroscopy (
1H-
MRS), is approximately three- to fivefold higher compared
with that of controls [13]. Occasional reports on liver
biopsies in FHBL patients have revealed moderate to severe
steatosis, in some patients associated with mild inflamma-
tion and fibrosis [11, 14]. However, hepatic triacylglycerol
accumulation in FHBL, unlike in NAFLD, occurs predom-
inantly independently of obesity-induced metabolic
derangements [15]. For this reason FHBL patients provide
a unique opportunity to investigate the relation between
IHTG content and insulin sensitivity in humans.
In a previous study, hepatic steatosis in non-obese FHBL
patients was associated with larger areas under the insulin
curves of a 2 h glucose tolerance test when compared with
healthy controls, although the difference was not statisti-
cally significant [13, 15]. In another study, insulin sensitiv-
ity, assessed using the HOMA index, was similar in non-
obese patients with FHBL compared with healthy controls
[14]. More recently, Amaro et al. [16] showed that, during a
hyperinsulinaemic–euglycaemic clamp, hepatic and periph-
eral insulin sensitivity did not differ between three obese
participants with FHBL and six obese controls without
hepatic steatosis.
In the present report we describe the results of an extensive
study of glucose and fat metabolism in patients with FHBL.
We performed a two-step hyperinsulinaemic–euglycaemic
clampwithstableisotopestodeterminehepatic andperipheral
insulin sensitivity and total triacylglycerol lipolysis. In
addition we measured intrahepatic triacylglycerol (IHTG)
content and intramyocellular lipid (IMCL) content by mag-
netic resonance spectroscopy (MRS) and determined body fat
distribution using dual energy X-ray absorptiometry and
abdominal computed axial tomography.
Methods
Subjects We included seven male patients with documented
FHBL and hepatic steatosis and seven healthy controls. We
were not able to recruit more participants because of the
low prevalence of FHBL and the strict inclusion criteria.
Four of the FHBL patients had the same mutation in the
APOB gene (11712delC). Two of these patients were
brothers. The mutations identified in the other FHBL
patients were 2534delA, Q1309X and 2783delC, respec-
tively [17]. Patients and controls were matched for age, sex,
BMI and WHR. Persons who performed regular exercise
above sedentary level and those who were regularly using
>3 units of alcohol per day or any recreational drug
during the last 30 days were excluded from participation.
Participants did not have any somatic illnesses, nor did they
use supplements or medication influencing glucose or lipid
metabolism. Oral glucose tolerance tests were within the
normal range (<7.8 mmol/l) according to the criteria of the
ADA [18]. All control participants had a normal routine
blood examination.
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pants. The study protocol was approved by the local
institutional review board. Patients were recruited from
the outpatient clinic of the Academic Medical Center,
Amsterdam, the Netherlands. Healthy volunteers were
recruited via local advertisements.
Hyperinsulinaemic–euglycaemic clamp After an overnight
fast, participants were admitted to the metabolic ward of the
Academic Medical Center at 07:30 hours. Prior to the study
day, all participants consumed at least 250 g of carbohy-
drates for 3 days and refrained from vigorous exercise for
1 week. A catheter was inserted into an antecubital vein for
infusion of stable isotope tracers, insulin and glucose.
Another catheter was inserted into a contralateral hand vein
and kept in a thermoregulated (60°C) Plexiglas box for
sampling of arterialised venous blood. Saline was infused
as NaCl 0.9% at a rate of 50 ml/h to sustain catheter
patency. [6,6-²H2]Glucose and [1,1,2,3,3-
2H5]glycerol were
infused as tracers (>99% enriched; Cambridge Isotopes,
Andover, MA, USA) to study glucose kinetics and lipolysis
(total triacylglycerol hydrolysis), respectively.
At time 0 (08:00 hours) blood samples were drawn
for determination of background enrichments. A primed
continuous infusion of isotopes was then started ([6,6-²H2]-
glucose and [1,1,2,3,3-
2H5]glycerol, both at a rate of
0.11 μmol kg
−1 min
−1, with a priming dose equivalent to
80 min of infusion) and continued until the end of the study.
After an equilibration time of 2.5 h, three blood samples were
taken for the measurement of isotope enrichments and one for
the measurement of glucoregulatory hormones and NEFA.
Thereafter, a two-step hyperinsulinaemic–euglycaemic clamp
was started. A continuous infusion of insulin (Actrapid
100 U/ml; Novo Nordisk Farma, Alphen aan de Rijn, the
Netherlands) was started for 2 h and 10 min at the rate of
20 mU [m
2 body surface area]
−1min
–1, followed by an
infusion of insulin at a rate of 60 mU [m
2 body surface
area]
−1min
–1 for another 2 h and 10 min. Plasma glucose
levels were measured every 5 min at the bedside. Glucose
was infused as 20% glucose at a variable rate, to maintain a
plasma glucose concentration of 5.0 mmol/l. [6,6-²H2]-
Glucose was added to the 20% glucose solution to achieve
glucose enrichments of 1% to approximate the values for
enrichment reached in plasma and thereby minimise changes
in isotopic enrichment due to changes in the infusion rate of
exogenous glucose [19]. During the last 40 min of both
hyperinsulinaemic periods, blood samples were drawn at
10 min intervals for determination of isotope enrichments,
glucoregulatory hormones and NEFA. During the study day,
participants remained fasted but were allowed to drink water.
Body composition and indirect calorimetry Body composi-
tion was measured by bioelectrical impedance analysis
(Maltron BF906; Maltron, Rayleigh, UK). Peripheral and
trunk fat mass were quantified by dual-energy X-ray
absorptiometry (QDR-4500W, software version whole body
v8.26A: 5, Hologic, Bedford, MA, USA).
For determination of visceral and abdominal fat mass, a
standardised single slice abdominal CAT-scan was per-
formed through the level of the fourth lumbar vertebra
(MX8000, Brilliance, Philips, Best, the Netherlands).
Oxygen consumption (  VO2)a n dC O 2 production
(  VCO2) were measured with the ventilated hood tech-
nique (model 2900; Sensormedics, Anaheim, CA, USA).
 VO2 and  VCO2 were measured continuously during the
final 30 min of the basal state and during the final 30 min
of step 2 of the hyperinsulinaemic–euglycaemic clamp.
The mean values of  VO2 and  VCO2 during the final
20 min were used for the calculation of glucose and fat
oxidation.
In vivo
1H-MRS IHTG content was measured by
1H-MRS.
We hypothesised that the reduced delivery of VLDL
triacylglycerols to peripheral tissues in FHBL might be
associated with reduced storage of triacylglycerols in
skeletal muscle. Therefore, we also measured intramyocel-
lular lipid content in the soleus muscle. Measurements were
performed after an overnight fast, within a 2 week time
frame before or after the clamp test. For logistical reasons,
scanning was performed at two separate sites with two
different scanners. ¹H-MRS spectra were acquired using a
3.0 T Magnetom Trio (Siemens, Erlangen, Germany) and a
3.0 T Intera (Philips, Best, the Netherlands). Identical
scanning parameters were used in both situations. During
the measurements, participants remained in the supine
position within the MRI scanner.
For the measurement of IMCL content, the soleus
muscle of the right leg was positioned within the
homogeneous volume of the magnet. Scout images were
acquired in order to position the volume of interest
15 cm beneath the tibia plateau. Two-dimensional
chemical shift imaging MRS data were collected using
a point-resolved spectroscopy sequence (PRESS) with
the following parameters: repetition time (TR) 1,100 ms,
echo time (TE) 30 ms, 10 mm slice thickness, 32×32
matrix size, field of view 16×16 cm, acquisition time
13 min, one acquisition. Spectra with and without water
suppression were obtained. A number of voxels ranging
from 5 to 27 inside the soleus were selected for further
analysis and were processed using the freely available
3DiCSI package (version 1.9.11; Columbia University,
New York, NY, USA). The number of voxels selected for
analysis was similar between the two sites. Chemical
shifts were reported using water as the internal standard
at 4.65 ppm. Average spectra were then processed using
specialised computer software (jMRUI 2.2) [20]. Three
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lipid content (CH2 and CH3) peaks. Lipid content was
calculated from the peak areas of IMCL CH2 (methylene)
at 1.3 ppm. IMCL contents were then expressed as the
percentage of water content. In one FHBL patient
quantification of IMCL content was impossible because
of a large extramyocellular lipid content.
IHTG content was obtained using single-voxel ¹H-MRS,
using a body array coil as the transmitter and phased
surface coils as receivers. MRS measurements were
acquired during breathhold, using single-voxel stimulated
acquisition mode (TE/TR 20/3,000 ms, six acquisitions).
Volumes of interest in the liver were located away from
major vascular structures and bile ducts. Voxel size was
27 mm
3. The water and fat resonance peaks, located at 4.65
and 1.3 ppm, were integrated using jMRUI software [20]
and relative fat content was expressed as the ratio of the fat
peak area over the cumulative water and fat peak areas.
Calculated peak areas of water and fat were corrected for
T2 relaxation (T2water, 34 ms; T2fat, 68 ms) [21] and the
percentage hepatic fat content was calculated according to
Szczepaniak et al. [22].
Glucose and lipid metabolism measurements Plasma glucose
concentrations were measured with the glucose oxidase
method using a Biosen C-line plus glucose analyser (EKF
Diagnostics, Barbleben/Magdeburg, Germany). Plasma
NEFA concentrations were determined with an enzymatic
colorimetric method (NEFA-C test kit; Wako Chemicals,
Neuss, Germany) with intra-assay variation of 1%, inter-
a s s a yv a r i a t i o no f4 –15% and a detection limit of
0.02 mmol/l. [6,6-
2H2]Glucose enrichment (tracer-to-tracee
ratio) was measured as described by Ackermans et al. [23].
[6,6-
2H2]Glucose enrichment intra-assay variation was 0.5–
1% with an inter-assay variation of 1% and a detection limit
of 0.04%. [1,1,2,3,3-
2H5]Glycerol enrichment was deter-
mined as described earlier [24]. Intra-assay variation was
1–3% for glycerol and 4% for [1,1,2,3,3-
2H5]glycerol;
inter-assay variation was 2–3% for glycerol and 7% for
[1,1,2,3,3-
2H5]glycerol.
Glucoregulatory hormones Insulin and cortisol were deter-
mined on an Immulite 2000 system (Diagnostic Products,
Los Angeles, CA, USA). Insulin was measured with a
chemiluminescent immunometric assay with intra-assay
variation of 3–6%, inter-assay variation of 4–6% and
detection limit of 15 pmol/l. Cortisol was measured with a
chemiluminescent immunoassay with intra-assay variation
of 7–8%, inter-assay variation of 7–8% and a detection
limit of 50 nmol/l. Glucagon was determined with the
Linco 125I RIA (Linco Research, St Charles, MO, USA)
with an intra-assay variation of 9–10%, inter-assay varia-
tion of 5–7% and detection limit of 15 ng/l.
Calculations and statistics HOMA of insulin resistance
(HOMA-IR) was calculated using the formula described
previously by Matthews et al. [25]. Endogenous glucose
production (EGP) and peripheral glucose uptake (rate of
disappearance [Rd]) were calculated using the modified
forms of the Steele equations as described previously [19,
26]. EGP and Rd were expressed as μmol(kg FFM)
−1min
−1
(FFM, fat-free mass). Insulin clearance was calculated as
the rate of insulin infusion (mU [m
2 body surface area]
−1
min
−1) divided by the mean plasma insulin concentration
during the clamp [27]. Total triacylglycerol hydrolysis/
lipolysis (glycerol turnover) was calculated using formulas
for steady-state kinetics adapted for stable isotopes [24, 26]
and was expressed as μmol kg
−1min
−1.
Resting energy expenditure (REE), glucose oxidation
and fat oxidation rates were calculated from  VO2 and
 VCO2 as reported previously [28]. Non-oxidative glucose
disposal was calculated as the difference between total
glucose disposal and glucose oxidation.
All data were analysed with non-parametric tests.
Comparisons between groups were performed using the
Mann–Whitney U test. SPSS version 14.0.2 (SPSS,
Chicago, IL, USA) was used for statistical analysis. Data
are presented as median (minimum–maximum). In the
Electronic supplementary material (ESM) data are also
presented as mean ± SEM.
Results
Study participants We included seven male FHBL partici-
pants and seven healthy male controls. All patients were
matched to controls for age, BMI and WHR. The baseline
characteristics of the participants are listed in Table 1 and
ESM Table 1. As expected, there was a significant
difference in plasma levels of ApoB, LDL-cholesterol and
triacylglycerol. In addition, plasma levels of alanine
aminotransferase and aspartate aminotransferase were
above the reference value, of 45 and 40 U/l respectively,
in some FHBL patients but not in controls. The HOMA
index tended to be higher in FHBL patients compared with
controls, although the difference was not statistically
significant.
Body composition and
1H-MRS Participants with FHBL did
not differ in body composition from their matched controls
(Table 2 and ESM Table 2).
1H-MRS measurements showed
moderate hepatic steatosis in all participants with FHBL and
mild steatosis in two control patients. As expected, IHTG
content was significantly higher in participants with FHBL
(29.8% [15.9–38.0%]) compared with controls (0.8% [0.0–
12.4%]) (p<0.005; Fig. 1a). One FHBL patient showed a
substantially higher IMCL content compared with all other
2116 Diabetologia (2011) 54:2113–2121participants but median IMCL concentrations did not
significantly differ between groups (patients 7.7% [4.5–
10.1%], controls 5.1% [3.3–21.4%]; not significant) (Fig. 1b).
Glucose metabolism Data on glucose metabolism are
summarised in Table 3 and ESM Table 3.
At baseline, plasma glucose was comparable between
groups, whereas insulin levels tended to be higher in
participants with FHBL compared with controls.
EGP at baseline was 11.5 (10.1–13.2) μmol (kg FFM)
−1
min
−1 in patients and 13.0 (11.4–14.0) μmol(kg FFM)
−1
min
−1 in controls (p=0.3). Insulin infusion during the first
step of the clamp procedure increased plasma insulin
concentrations to 199 (177–302) pmol/l in FHBL partici-
pants and to 162 (132–294) pmol/l in healthy controls
(p=0.2). During the second step of the clamp procedure
insulin concentrations increased to 615 (572–836) pmol/l in
FHBL and to 504 (426–712) pmol/l in control participants
(p=0.1).
Plasma levels for other glucoregulatory hormones, e.g.
cortisol and glucagon, were comparable between groups
both in the basal state and during the clamp (data not
shown).
The ability of insulin to suppress endogenous glucose
production was not impaired in FHBL patients compared
with controls. At lower levels, insulin-mediated suppression
of EGP was 68.6% (59.3–82.8%) in patients and 72.9%
(56.8–86.9%) in controls (p=0.9; Fig. 2a). During higher
dose insulin infusion EGP was completely suppressed in
both groups.
The ability of insulin to increase peripheral glucose
disposal was also not significantly impaired in patients with
FHBL compared with controls (Fig. 2b). Correction of Rd
for plasma insulin did not have an effect on our results (data
not shown). Insulin clearance did not differ significantly
between patients and controls during either step of the
clamp.
REE, the basal rate of glucose oxidation and the insulin-
stimulated increase in glucose oxidation and non-oxidative
glucose disposal were similar between groups (Table 3 and
ESM Table 3).
NEFA and lipolysis In the basal state, circulating concen-
trations of NEFAs were not different between patients and
control participants (Table 3 and ESM Table 3). Likewise,
lipolysis (glycerol turnover) and lipid oxidation were
Characteristic FHBL (n=7) Control (n=7) p value
Age (years) 47 (22–61) 45 (22–60) NS
BMI (kg/m
2) 27 (22–32) 26 (20–36) NS
WHR (cm) 1.02 (0.97–1.05) 1.01 (0.94–1.12) NS
Total cholesterol (mmol/l) 1.94 (1.39–2.81) 4.75 (3.47–5.23) <0.01
Triacylglycerol (mmol/l) 0.14 (0.05–0.49) 0.76 (0.40–1.07) <0.01
ApoB (g/l) 0.24 (0.12–0.4) 0.83 (0.54–0.90) <0.01
HDL (mmol/l) 1.19 (0.7–1.53) 1.3 (0.79–1.83) NS
HOMA index 1.58 (0.21–2.35) 0.76 (0.23–1.58) NS
Aspartate aminotransferase (U/l) 39 (22–49) 28 (14–34) <0.05
Alanine aminotransferase (U/l) 62 (22–106) 23 (10–32) 0.05
C-reactive protein (mg/l) 1.4 (0.50–3.10) 1.0 (0.50–6.20) NS
Table 1 Baseline characteristics
of FHBL patients and healthy
controls
Data are median (range)
Variable FHBL Controls p value
Body weight (kg) 86 (70–110) 87 (71–114) NS
Body fat (%) 26 (19–30) 23 (12–35) NS
Lean body mass (kg) 61 (49–77) 64 (58–67) NS
Peripheral fat mass (kg) 8.4 (5.7–14.1) 8.6 (3.9–16.6) NS
Trunk fat mass (kg) 11.7 (6.1–16.7) 10.8 (3.6–19.9) NS
Abdomen
Subcutaneous adipose tissue (cm
2) 189.31 (148.43–429.06) 203.35 (47.76–504.59) NS
Visceral adipose tissue (cm
2) 124.20 (38.71–180.71) 106.61 (26.46–218.99) NS
Visceral:subcutaneous adipose tissue ratio 0.62 (0.26–1.19) 0.55 (0.22–1.08) NS
Table 2 Body fat composition
Data are median (range)
Diabetologia (2011) 54:2113–2121 2117comparable between patients and controls both in the basal
state and during the clamp.
Baseline lipolysis corrected for REE did not have an
effect on the results (data not shown). Furthermore,
lipolysis tended to be less suppressed by insulin in
patients 60% (37–73%) compared with controls 66%
(55–75%), although the difference was not statistically
significant (p=0.09; Fig. 2c).
Discussion
In the present study we show that patients with FHBL,
despite the presence of moderate to severe hepatic steatosis,
do not display a decrease in hepatic or peripheral insulin
sensitivity compared with unaffected, matched controls.
This indicates that hepatic triacylglycerol accumulation in
itself is not causally related to hepatic or peripheral insulin
resistance.
In the basal state, HOMA-IR tended to be higher in
FHBL patients compared with controls. Since glucose
levels were similar between patients and controls, the
difference in HOMA-IR is probably explained by higher
basal insulin levels in patients than in controls and is
most likely caused by reduced insulin clearance and not
by increased insulin secretion. This would be in line with
earlier observations in non-diabetic participants, in whom
hepatic fat accumulation was shown to be associated
with impaired insulin clearance, independently of obesity
[27]. A tendency towards higher insulin levels in FHBL
patients was also observed during the hyperinsulinaemic
clamp. Although calculation of insulin clearance during
the clamp failed to show a significant difference between
patients and controls, this finding further supports the
concept that insulin clearance may be decreased in
patients with FHBL.
It should be noted that when Rd was corrected for
circulating plasma insulin levels, peripheral insulin sensitivity
in FHBL patients did not differ from that in controls. Thus,
despite a possible difference in insulin clearance, insulin-
mediated peripheral glucose uptake was not impaired in
patients with FHBL.
Two of the seven patients in the control group showed
mild hepatic steatosis, of 12% and 8%, respectively. One
could argue that increased IHTG content in these patients
might, to some extent, have skewed the data. However,
since patients and controls were matched, individuals could
not be excluded from analysis.
In a recent small study it was shown that both the hepatic
insulin sensitivity index (inverse of the product of the basal
EGP and fasting plasma insulin concentration) and the
insulin-mediated increase in Rd did not differ between three
obese participants with FHBL and six obese controls
without hepatic steatosis [16]. In that study only a high-
dose insulin infusion (50 mU/m
2) was used during the
clamp. In the present study we extended these findings in a
larger number of patients, including both lean and obese
FHBL patients, and carefully matched controls. Moreover,
by using both a high- and a low-dose insulin infusion we
were able to unambiguously demonstrate that FHBL does
not affect hepatic insulin sensitivity. In addition, we show
that FHBL does not lead to impaired sensitivity in other
target pathways of insulin, e.g. glucose oxidation, non-
oxidative glucose disposal, lipolysis and lipid oxidation.
Thus, our data provide strong evidence to show that in
patients with FHBL, hepatic steatosis is a determinant of
neither hepatic nor peripheral (muscle or adipose tissue)
insulin resistance.
The lack of hepatic insulin resistance in FHBL in
spite of severe steatosis may be surprising. Absence of
insulin resistance has, however, been observed previously
in animal models of hepatic steatosis [29]. In these
animals, overabundance of hepatic diacylglycerol acyl-
transferase, an enzyme catalysing the final step in
triacylglycerol synthesis [30]; deletion of long-chain fatty
acid elongase family member 6 (ELOVL6), a microsomal
enzyme involved in the elongation of fatty acids [31];
deletion of microsomal triacylglycerol transfer protein,
responsible for the assembly of triacylglycerol-rich lipo-
proteins [32]; and pharmacological blockade of hepatic
fatty acid β-oxidation [33], have all been associated with
the induction of hepatic steatosis without hepatic or
peripheral insulin resistance.
If hepatic steatosis in itself does not cause insulin
resistance, factors other than hepatic triacylglycerol accu-
mulation must be responsible for the close relation between
these two entities in epidemiological studies [1, 4, 6–8].
Thus, hepatic steatosis and insulin resistance could repre-
sent two separate manifestations of the same metabolic
derangements, such as chronic inflammation, endoplasmic
reticulum stress or stress caused by other, as yet unidenti-
fied, metabolites [34, 35]. Recent studies have put forward
the concept that lipid metabolites such as fatty acids, long-
Fig. 1 IHTG and IMCL content assessed by MRS in participants with
FHBL and healthy controls. The horizontal line represents the median.
a Intrahepatic triacylglycerol (IHTG) content (p<0.005). b Intra-
myocellular lipid content (IMCL) content (NS)
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Diabetologia (2011) 54:2113–2121 2119chain acyl-CoAs, diacylglycerol and ceramides rather than
triacylglycerols themselves [36, 37] are determinants of the
onset of insulin resistance [29, 38–40]. In this scenario,
hepatic steatosis in FHBL may be the result of a harmless
accumulation of triacylglycerols, whereas NAFLD is the
result of an accumulation of toxic lipid metabolites leading
to insulin resistance. In the present study, circulating
concentrations of NEFA were similar in FHBL patients
compared with controls.
Furthermore, the association between hepatic steatosis
and insulin resistance may have a genetic basis. For
example, polymorphisms in APOC3 have recently been
shown to be associated with both NAFLD and insulin
resistance, whereas the single-nucleotide polymorphism
rs738409 in PNPLA3 was associated with increased liver
fat but not with insulin resistance [41, 42]. Unfortunately,
the results of the present study do not provide answers to
explain the true mechanism underlying the relationship
between hepatic steatosis and insulin resistance.
Hepatic steatosis has been suggested to be causally
related to hepatic as well as peripheral insulin resistance.
In the present study, we convincingly show in a unique
human model of severe fatty liver disease that hepatic
steatosis is not associated with hepatic or peripheral
insulin resistance. Whereas the results of the present
study do not unravel the exact mechanisms underlying
the complex relationship between these two highly
prevalent metabolic disorders, further studies focusing
on the comparison of different hepatic steatosis models
in large cohorts are required.
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